GB2383329A - Lipo-or amphiphilic scintillators and their use in assays - Google Patents

Lipo-or amphiphilic scintillators and their use in assays Download PDF

Info

Publication number
GB2383329A
GB2383329A GB0306216A GB0306216A GB2383329A GB 2383329 A GB2383329 A GB 2383329A GB 0306216 A GB0306216 A GB 0306216A GB 0306216 A GB0306216 A GB 0306216A GB 2383329 A GB2383329 A GB 2383329A
Authority
GB
United Kingdom
Prior art keywords
scintillator
compounds
liposomes
cells
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0306216A
Other versions
GB0306216D0 (en
Inventor
John David Sutherland
Jonathan Michael Blackburn
Steven John Culliford
Roland Zbignieiw Kozlowski
Andrew James Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sense Proteomic Ltd
Original Assignee
Sense Proteomic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020503A external-priority patent/GB0020503D0/en
Application filed by Sense Proteomic Ltd filed Critical Sense Proteomic Ltd
Publication of GB0306216D0 publication Critical patent/GB0306216D0/en
Publication of GB2383329A publication Critical patent/GB2383329A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides scintillator molecules, consisting of one or more X moieties, which is a phosphor, covalently attached to one or more R<SP>1</SP> moieties which is a lipophilic or amphiphilic group, wherein the scintillator molecule is capable of integrating into a cell, a cell membrane, a biological membrane, an artificial membrane or a delivery vehicle and when integrated can act as a phosphor. Preferred scintillator molecules are of formula. Also provided are liposomes or micelles containing the novel scintillator compounds, methods for preparing the liposomes or micelles containing the novel scintillator compounds and the use of the liposomes or micelles as delivery vehicles to insert the scintillator compounds into the cell membranes of cells. In addition, the invention provides cells containing the novel scintillator compounds and the use of the cells in assay systems.

Description

(72) Inventor(s) John David Sutherland Jonathan Michael Biackburn Steven
John Culliford Roland Zbignieiw Koziowski Andrew James Sutherland 174) Agent and/or Address for Service Kilburn & Strode 20 Red Lion Street, LONDON, WC1R 4PJ, United Kingdom
GB0306216A 2000-08-18 2001-08-17 Lipo-or amphiphilic scintillators and their use in assays Withdrawn GB2383329A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020503A GB0020503D0 (en) 2000-08-18 2000-08-18 Compounds
US24799400P 2000-11-14 2000-11-14
PCT/GB2001/003695 WO2002014290A1 (en) 2000-08-18 2001-08-17 Lipo- or amphiphilic scintillators and their use in assays

Publications (2)

Publication Number Publication Date
GB0306216D0 GB0306216D0 (en) 2003-04-23
GB2383329A true GB2383329A (en) 2003-06-25

Family

ID=26244864

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0306216A Withdrawn GB2383329A (en) 2000-08-18 2001-08-17 Lipo-or amphiphilic scintillators and their use in assays

Country Status (10)

Country Link
EP (1) EP1315707A1 (en)
JP (1) JP2004506754A (en)
KR (1) KR20030066601A (en)
CN (1) CN1458925A (en)
AU (1) AU2001278633A1 (en)
BR (1) BR0113328A (en)
CA (1) CA2420006A1 (en)
GB (1) GB2383329A (en)
IL (1) IL154485A0 (en)
WO (1) WO2002014290A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553559B2 (en) * 2005-12-21 2009-06-30 Lg Display Co., Ltd. Hexatriene derivatives for use as blue emitting materials for organic electroluminescent devices
EP1892530A1 (en) * 2006-08-25 2008-02-27 Boehringer Ingelheim Pharma GmbH & Co. KG Method for determining transport activity of a transport protein
CN104327005B (en) * 2014-10-21 2016-08-24 华烁科技股份有限公司 The preparation method of 2,5-diphenyloxazole
AU2019368213A1 (en) * 2018-10-21 2021-06-03 Kansas State University Research Foundation Methods for generating therapeutic delivery platforms
WO2020197032A1 (en) * 2019-03-26 2020-10-01 동국대학교 산학협력단 Scintillator composition and scintilator using same
KR102288775B1 (en) * 2019-03-26 2021-08-12 동국대학교 산학협력단 Scintillator composition and Scintillator using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63227576A (en) * 1987-03-13 1988-09-21 Hamamatsu Photonics Kk Biphenyloxazole derivative, production and use thereof
WO2000020475A1 (en) * 1998-10-05 2000-04-13 The Nottingham Trent University Solid supports containing scintillant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63227576A (en) * 1987-03-13 1988-09-21 Hamamatsu Photonics Kk Biphenyloxazole derivative, production and use thereof
WO2000020475A1 (en) * 1998-10-05 2000-04-13 The Nottingham Trent University Solid supports containing scintillant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
29 December 1997 (1997-12-29), pages 9061-9064, XP004098158 the whole document *
CLAPHAM B ET AL: "Synthesis and scintillating efficiencies of 4-functionalised-2,5-diphenyloxazoles" TETRAHEDRON LETTERS, vol. 38, no. 52, *
PATENT ABSTRACTS OF JAPAN vol. 013, no.021 (c-560), 18 January 1989 (1989-01-18) & JP 63 227576 A (HAMAMATSU PHOTONICS KK) abstract *

Also Published As

Publication number Publication date
KR20030066601A (en) 2003-08-09
GB0306216D0 (en) 2003-04-23
AU2001278633A1 (en) 2002-02-25
IL154485A0 (en) 2003-09-17
EP1315707A1 (en) 2003-06-04
CN1458925A (en) 2003-11-26
WO2002014290A1 (en) 2002-02-21
BR0113328A (en) 2003-07-29
JP2004506754A (en) 2004-03-04
CA2420006A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
EP0968227B1 (en) Dimeric cationic lipids on dicystine basis
AU2002359122A1 (en) Novel compounds
EP1754703A3 (en) N-Heterocyclic derivatives as nos inhibitors
WO1997003939A1 (en) Novel amide-based cationic lipids
AU6779200A (en) Encapsulation of fluorescent particles
AU2001245945A1 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
Hamasaki et al. Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA–protein interactions derived from HIV-1 activators
CA2246456A1 (en) Lipids and their use, for example, in liposomes
CA2285918A1 (en) Methods for concentrating ligands using magnetic particles
WO2002046448A3 (en) Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
AU2002216063A1 (en) Membrane molecule indicator compositions and methods
IL136137A0 (en) Hydrophobically-modified protein compositions and methods
GB2383329A (en) Lipo-or amphiphilic scintillators and their use in assays
AU1530401A (en) Security system
EP1291055A3 (en) Sample processing method using ion exchange resin
ATE407703T1 (en) COMPOUNDS AND KITS FOR PRODUCING IMAGING AGENTS AND IMAGING METHODS
Kerkenaar On the antifungal mode of action of metalaxyl, an inhibitor of nucleic acid synthesis in Pythium splendens
DE69939171D1 (en) PHARMACEUTICAL COMPOSITIONS WITH TUMOR NEKROSE FACTOR AND 2-METHOXYESTRON-3-O-SULPHAMATE AS ESTRONE SULPHATASE INHIBITORS
CA2286177A1 (en) Composition for gene transfer into cells
ATE208369T1 (en) NEW LIPOPOLYAMINES, THEIR PRESENTATION AND APPLICATION
AU3721095A (en) Cationic transport reagents
ATE222884T1 (en) CHEMICAL CONSTRUCTIONS AND THEIR USES
WO2002053583A3 (en) Amphipathic peptides and their use for transferring substances of interest into cells
ATE361374T1 (en) REPORTER COMPOUNDS AND METHODS FOR DETERMINING THE LIPIDIZATION STATUS OF A CELL
Lee et al. Formation of high axial ratio microstructures from peptides modified with glutamic acid dialkyl amides

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)